Phio Pharmaceuticals Corp (PHIO) is experiencing a surge in stock price following the announcement of new data on its lead clinical product candidate, PH-762. PH-762, an INTASYL compound, has shown promising results in preclinical studies, indicating its potential as a neoadjuvant therapy for treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.